Italian pharma Chiesi is fertilizing Arbor’s rare disease efforts, inking a gene therapy deal potentially worth more than $2 billion.

The 2025 Nobel Prize in Physiology or Medicine has been awarded to three pioneering immunologists for their work on regulatory T cells, including two who conducted their winning work at a British biotech.

Takeda is tapping out of the cell therapy arena as part of a "strategic portfolio reprioritization," with 137 roles at a Massachusetts R&D site affected. https://t.co/4HWZbOsLyI

No funding deal in sight following high-stakes White House negotiations, party leaders say https://t.co/cjdqiHEwUT

The GLP-1 agonist at the center of Pfizer’s upfront $4.9 billion buyout of Metsera has been tied to 14.1% weight loss at 28 weeks as well as “potentially class-leading tolerability,” according to the biotech. $PFE

MoonLake’s stock has taken a pummeling after the biotech blamed an unexpectedly high placebo response rate for its much-hyped inflammatory disease prospect missing the key goal in a phase 3 study. $MLTX

IO Biotech has resorted to halving its workforce after the FDA knocked back its plans to seek approval for its cancer vaccine. $IOBT

White House preps agencies for mass layoffs if government shuts down: media reports https://t.co/aRQilLD24Y

Eli Lilly has pulled the plug on a phase 2b obesity trial before enrolling a single patient, citing “strategic business reasons.” $LLY

For the first time, Congressional lawmakers join "Podnosis"! Two members of the Democratic Women's Caucus chat w/ @emmabeavins about the impact of Medicaid cuts and efforts to work across the aisle on healthcare reform https://t.co/RBGto80n8G

One of this year's Fierce 15 winners is Alentis Therapeutics. The company is harnessing the power of anti-Claudin-1 technology for cancer and organ scarring.

UniQure has set its sights on submitting its Huntington’s disease gene therapy for approval next year after the asset was shown to slow disease progression by 75% in a phase 1/2 trial. $QURE

Introducing Fierce Biotech’s 2025 class of Fierce 15 winners. From advancing radically new therapies to refining existing modalities, this year’s companies are pushing the envelope and giving us a reason for optimism.

The FDA has approved Stealth BioTherapeutics’ treatment for the ultrarare disease Barth syndrome, marking the peptide as the first therapy for the condition. @FiercePharma coverage here ⬇️

Novo Nordisk pads case for Wegovy in a pill as oral obesity asset nears FDA decision

One of the top fundraisers of 2024 is halving its workforce about a year after drawing in a $325 million series C.

VectorY Therapeutics has seen the shape of things to come... and it involves finding fresh ways to deliver its gene therapies into the brain. https://t.co/8Yu4NEb5kt

Despite submitting their oral PROTAC candidate to the FDA for approval just last month, Pfizer and Arvinas want to wash their hands of the drug. $PFE $ARVN https://t.co/NpOgCDEoXP

British Big Pharma GSK is welcoming President Donald Trump to the U.K. with a hefty gift: a five-year, $30 billion planned investment in U.S. R&D and manufacturing. Story cross-posted from @FiercePharma ⬇️ https://t.co/4BOLpKGZmD

Regeneron is racing to regulators after reporting a phase 3 win in an ultrarare disease. $REGN